MERCK'S KEYTRUDA SUCCESSFUL IN MULTIPLE TYPES OF ENDOMETRIAL CANCER
- A phase 3 trial found that Merck's Keytruda (pembrolizumab) was effective in improving progression-free survival as a first-line treatment for endometrial cancer regardless of mismatch repair status.
- The oncologic is currently approved for those with microsatellite instability-high (MSI-H) and mismatch repair deficient (dMMR) endometrial cancer.
- The new results found that after median follow-up of 7.9 months, Keytruda plus chemotherapy reduced the risk of disease progression or death by 46% in patients whose cancer was mismatch repair proficient (pMMR) compared to chemo alone. In those who were dMMR, the figure was 70%. In that cohort, median follow-up was 12 months.
- The results have been published in the New England Journal of Medicine.
- Read why Seeking Alpha contributor BiotechValley Insights recently initiated Merck with a buy.
Now read: Supreme Court hears arguments in Amgen Repatha patent case against Sanofi